Literature DB >> 1888220

The chemotherapy of rodent malaria. XLVI. Reversal of mefloquine resistance in rodent Plasmodium.

W Peters1, B L Robinson.   

Abstract

Multiple drug resistance in Plasmodium falciparum is already showing evidence of extending to mefloquine, which at present is one of the few alternative antimalarials for the prevention or treatment of infection with such parasites. Neither verapamil nor cyproheptadine, which reverse chloroquine (CQ) resistance in P. falciparum and in rodent malaria parasites, reverse resistance to mefloquine (MEF) in the MEF-resistant NS/1100 line of P. yoelii ssp. NS. On the other hand, such resistance is clearly reversed when mefloquine is administered to infected mice together with penfluridol.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1888220     DOI: 10.1080/00034983.1991.11812525

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  4 in total

Review 1.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

2.  Enhancement of drug susceptibility in Plasmodium falciparum in vitro and Plasmodium berghei in vivo by mixed-function oxidase inhibitors.

Authors:  A M Ndifor; R E Howells; P G Bray; J L Ngu; S A Ward
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

3.  Fluoxetine hydrochloride enhances in vitro susceptibility to chloroquine in resistant Plasmodium falciparum.

Authors:  L Gerena; G T Bass; D E Kyle; A M Oduola; W K Milhous; R K Martin
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

4.  Evidence for the contribution of the hemozoin synthesis pathway of the murine Plasmodium yoelii to the resistance to artemisinin-related drugs.

Authors:  Benoit Witkowski; Joel Lelièvre; Marie-Laure Nicolau-Travers; Xavier Iriart; Patrice Njomnang Soh; Fatima Bousejra-Elgarah; Bernard Meunier; Antoine Berry; Françoise Benoit-Vical
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.